Effects of GCP on Prostate Cancer.
Status
Conditions
Treatments
Details and patient eligibility
About
Genistein Combined Polysaccharide (GCP) is derived from adding soy powder to shiitake mushrooms. This concentrated mixture is currently being sold in Japan and the United States and is thought to possibly contain properties that may be useful in treating certain types of cancer.
Sex
Volunteers
Inclusion criteria
Participants must be male and have a pathological diagnosis of prostate cancer.
No treatment (surgery [RRP], radiation, or hormones) prior to study entry.
The patient has decided, after consultation with his own doctor, to have no treatment intervention (surgery [RRP], radiation, or hormones) for the next six months.
PSA between 2.0 and 10.0 ng/ml.
If PSA is >10.0, patient must have been on Active Surveillance for 12 months prior to study initiation.
No known allergy to soy or soy products.
The patient is not currently taking more than 2 grams of genistein a day in nutritional or diet enhancing supplements (OTC supplements).
Exclusion criteria
No pathological documentation of prostate cancer.
Allergy to soy or soy products
Prior history of treatment for prostate cancer.
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal